Stock exchange

Melco sustainability strategy ‘Above & Beyond’ honored by PATA Gold Awards and International Gaming Awards

Friday, September 17, 2021 - 10:02am

The Above and Beyond sustainability strategy ensures that Melco achieves carbon neutrality and zero waste across all its global resorts by 2030.

Key Points: 
  • The Above and Beyond sustainability strategy ensures that Melco achieves carbon neutrality and zero waste across all its global resorts by 2030.
  • Ms. Denise Chen, Senior Sustainability Adviser of Melco, said, We are thrilled to be recognized by PATA and IGA for our commitment towards Sustainability.
  • PATA Gold Awards 2021 attracted a total of 113 entries from 51 travel and tourism organizations and individuals.
  • The International Gaming Awards recognizes excellence across the gaming industry and is supported by renowned players from all tiers of the industry.

GBA Business School Under Edvantage Group Officially Founded, Further Expansion in the Guangdong-Hong Kong-Macao Greater Bay Area

Wednesday, September 15, 2021 - 9:55am

After the lighting ceremony, GBA Business School signed two MOUs with Guangdong-Hong Kong-Macao Bay Area Entrepreneurs Union and Hong Kong Cyperport respectively.

Key Points: 
  • After the lighting ceremony, GBA Business School signed two MOUs with Guangdong-Hong Kong-Macao Bay Area Entrepreneurs Union and Hong Kong Cyperport respectively.
  • GBA Business School has held a series of seminars entitled "New Strategic Thinking for the Greater Bay Area" for the past year, with leaders invited from different sectors in the Greater Bay Area to share their practical experiences and insights.
  • With these, GBA Business School hopes to cultivate more future leaders and talents in different areas for the benefit of the Greater Bay Area.
  • In addition, the Group also operates Greater Bay Area Business School (vocational education institution) in Hong Kong, China.

Hua and Sinopharm Announced Supply Chain Strategic Cooperation

Wednesday, September 15, 2021 - 6:35am

SHANGHAI, CHINA, Sept 15, 2021 - (ACN Newswire) - On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099).

Key Points: 
  • SHANGHAI, CHINA, Sept 15, 2021 - (ACN Newswire) - On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099).
  • Hua Medicine will rely on Sinopharm's nation-wide drug distribution network to carry out in-depth cooperation in supply chain management.
  • "We are very glad to witness the strategic cooperation between Sinopharm and Hua Medicine, opening a new chapter on our cooperation.
  • In recent years, Sinopharm continue to innovate and build up the new ecosystem of the smart pharmaceutical and supply chain, improving the efficiency of supply chain.

Legend Capital Led a New Round of Investment of Etana

Tuesday, September 14, 2021 - 12:42am

HONG KONG, Sept 14, 2021 - (ACN Newswire) - Legend Capital led a new round of investment of PT Etana Biotechnologies Indonesia (Etana), along with Innovent Biologics, Inc. (Innovent) (HKEX: 01801), and a consortium led by UOB Venture Management (UOBVM).

Key Points: 
  • HONG KONG, Sept 14, 2021 - (ACN Newswire) - Legend Capital led a new round of investment of PT Etana Biotechnologies Indonesia (Etana), along with Innovent Biologics, Inc. (Innovent) (HKEX: 01801), and a consortium led by UOB Venture Management (UOBVM).
  • Hong Tan, Managing Director of Legend Capital, said "We appreciate Etana's vision to provide Indonesia with cost-effective biopharmaceuticals.
  • Legend Capital is an independent professional venture capital company under Legend Holdings.
  • Its core business is positioned at the initial stage of venture capital and expansion stage growth investment.

HUTCHMED Receives Breakthrough Therapy Designation in China for Amdizalisib (HMPL-689) for Treatment of Relapsed or Refractory Follicular Lymphoma

Monday, September 13, 2021 - 7:00am

This indicates that the development and review of amdizalisib for relapsed or refractory FL may be expedited, to address patients' unmet needs more quickly.

Key Points: 
  • This indicates that the development and review of amdizalisib for relapsed or refractory FL may be expedited, to address patients' unmet needs more quickly.
  • In April 2021, HUTCHMED initiated a Phase II registration study in China for amdizalisib in approximately 100 patients with relapsed or refractory FL and approximately 80 patients with marginal zone lymphoma (MZL).
  • Amdizalisib is also being evaluated in an ongoing Phase I/Ib study in the U.S. and Europe in patients with relapsed or refractory NHL ( NCT03786926 ).
  • Patients with relapsed or refractory FL do not have curative treatment options and have a high unmet need for optimal therapeutic options.

IntelliCentrics Achieves Perfect Score on CVO Certification from NCQA

Friday, September 10, 2021 - 3:00pm

NCQAs CVO Certification includes comprehensive on-site evaluations conducted by a team of healthcare professionals and certified credentialing specialists.

Key Points: 
  • NCQAs CVO Certification includes comprehensive on-site evaluations conducted by a team of healthcare professionals and certified credentialing specialists.
  • A national oversight committee of physicians analyzes the teams findings and determines certification based on the CVOs compliance with the NCQA Standards.
  • Achieving CVO certification from NCQA demonstrates that IntelliCentrics has the systems, process, and personnel in place to thoroughly and accurately verify providers credentials and help health plan clients meet their accreditation goals, stated Margaret E. OKane, President, NCQA.
  • NCQA can be found online at ncqa.org , on Twitter @ncqa , on Facebook at facebook.com/NCQA.org/ and on LinkedIn at linkedin.com/company/ncqa .

HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference

Tuesday, September 7, 2021 - 9:30am

HUTCHMED has initiated an extensive, globally-focused clinical development pathway for amdizalisib.

Key Points: 
  • HUTCHMED has initiated an extensive, globally-focused clinical development pathway for amdizalisib.
  • Savolitinib is an oral, potent, and highly selective mesenchymal epithelial transition receptor (MET) tyrosine kinase inhibitor (TKI) that has demonstrated clinical activity in advanced solid tumors.
  • It is currently under clinical development for multiple tumor types, including lung, kidney, and gastric cancers, as a single treatment and in combination with other medicines.
  • In 2011, following its discovery and initial development by HUTCHMED, AstraZeneca and HUTCHMED entered a global licensing agreement to jointly develop and commercialize savolitinib.

ATAL Training Centre Officially Opens in Hong Kong

Tuesday, September 7, 2021 - 4:05am

HONG KONG, Sept 7, 2021 - (ACN Newswire) - Analogue Holdings Limited (stock code: 1977) together with its subsidiaries (referred to as "ATAL Engineering Group", "ATAL" or the "Group"), a leading electrical and mechanical ("E&M") engineering service provider in Hong Kong, is pleased to announce the official opening of its ATAL Training Centre ("ATC").

Key Points: 
  • HONG KONG, Sept 7, 2021 - (ACN Newswire) - Analogue Holdings Limited (stock code: 1977) together with its subsidiaries (referred to as "ATAL Engineering Group", "ATAL" or the "Group"), a leading electrical and mechanical ("E&M") engineering service provider in Hong Kong, is pleased to announce the official opening of its ATAL Training Centre ("ATC").
  • ATC officially opens to provide a dedicated training space to its employees.
  • Today, our ATAL Training Centre, which has taken some time to bring to fruition, sets an important milestone in our talent cultivation.
  • Established in 1977, ATAL Engineering Group ("ATAL") is a leading electrical and mechanical engineering service provider headquartered in Hong Kong, with operations in Macau, Mainland China, the UK and the US.

Daiwa Securities Upgrades Rating of Parent Company of Precision Tsugami (1651.HK) to "Outperform"

Monday, September 6, 2021 - 11:35am

HONG KONG, Sept 6, 2021 - (ACN Newswire) - Daiwa Securities, in its recently published research report, has upgraded the rating for the parent company of Precision Tsugami (China) Corporation Limited ("Precision Tsugami" or the "Company", stock code: 1651), which is the largest foreign-owned CNC high-precision machine tool manufacturer in the PRC .

Key Points: 
  • HONG KONG, Sept 6, 2021 - (ACN Newswire) - Daiwa Securities, in its recently published research report, has upgraded the rating for the parent company of Precision Tsugami (China) Corporation Limited ("Precision Tsugami" or the "Company", stock code: 1651), which is the largest foreign-owned CNC high-precision machine tool manufacturer in the PRC .
  • The "Outperform" rating was given to the firm as Daiwa Securities was particularly optimistic about Precision Tsugami's strong business foundation in the PRC, and the higher-than-expected number of orders received in July.
  • In the report, Daiwa Securities noted that Precision Tsugami brought a new plant on stream in Anhui Province, the PRC, in March 2021, thus increasing total production capacity by just above 15%.
  • In view of the higher-than-expected number of orders in July, Daiwa Securities raised its revenue forecast for the parent company of Precision Tsugami.

DGAP-News: ABOUT YOU Holding AG: ABOUT YOU welcomes inclusion into SDAX(R) index

Monday, September 6, 2021 - 12:39pm

Hamburg, 6 September 2021 - ABOUT YOU Holding AG ("ABOUT YOU") will be included into SDAX(R) via the Fast Entry rule less than three months after its initial listing.

Key Points: 
  • Hamburg, 6 September 2021 - ABOUT YOU Holding AG ("ABOUT YOU") will be included into SDAX(R) via the Fast Entry rule less than three months after its initial listing.
  • After the quarterly DAX(R) index review on 3 September 2021, Deutsche Brse has announced that ABOUT YOU will be added to SDAX(R) effective from 20September 2021.
  • The index consists of 70 smaller businesses, so-called small caps, which follow the companies included in DAX(R) and MDAX(R) with regards to their free float market capitalisation.
  • We are delighted about the higher visibility, which the inclusion into the index gives to our shares.